CDK1 serves as a potential prognostic biomarker and target for lung cancer
Authors:
Open Access
- 5 February 2020
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (2)
Abstract
Evidence from cell and mouse models and human tissues suggests that cyclin dependent kinase 1 (CDK1) is involved in lung cancer (LC) tumorigenesis. However, the different types of expression patterns and prognostic results of CDK1 need further analysis. In the current study, we assessed CDK1 expression and LC patient outcomes using data from the Oncomine, GEPIA, and Kaplan–Meier Plotter databases. Additionally, mutations in the CDK1 gene were analyzed by using the cBioPortal database. The expression of CDK1 was verified by real-time quantitative PCR using the Human Protein Atlas database and human tissues. Expression of CDK1 was higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in normal lung samples. Moreover, CDK1 expression was linked to disease progression. Survival analysis indicated that upregulation of CDK1 was related to poor overall survival, low first progression, and post-progression survival in patients with LC. Our results indicate that CDK1 is a potential clinical target and prognostic biomarker for patients with LC.Keywords
This publication has 25 references indexed in Scilit:
- Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal CancerMolecular Cancer Research, 2018
- New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapiesExpert Opinion on Emerging Drugs, 2017
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017
- Role of Autophagy and Apoptosis in Non-Small-Cell Lung CancerInternational Journal of Molecular Sciences, 2017
- Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2Molecular Cancer Therapeutics, 2016
- Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expressionBiochemical and Biophysical Research Communications, 2016
- Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer2015
- Targeting Mitosis in Cancer: Emerging StrategiesMolecular Cell, 2015
- Antibodies for profiling the human proteome—The Human Protein Atlas as a resource for cancer researchProteomics, 2012
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009